Simulations Plus (SLP) Buys Pro-ficiency Holdings for $100M

The transaction, valued at roughly $100 million in cash, signifies a strategic move for Simulations Plus in augmenting its footprint across the drug development continuum, from pre-clinical protocols to product commercialization. The acquisition solidifies Simulation Plus' portfolio, bolstering its scientific skills, drug development expertise, data management acumen, predictive analytics and biosimulation capabilities. Simulation Plus is a well-known name in the biosimulation market and consulting services ...